STOCK TITAN

Penumbra (PEN) Stock News, Oct 2025-Feb 2026

PEN NYSE

Penumbra, Inc. develops thrombectomy technologies for medical conditions involving blood clots, including ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Its product portfolio includes computer assisted vacuum thrombectomy and devices such as the Indigo System, Penumbra System Reperfusion Catheter, ACE Reperfusion Catheters, LANTERN Delivery Microcatheter, Penumbra Smart Coil, and Artemis Neuro Evacuation Device.

Recurring company news covers financial results, capital-structure updates, investor conference presentations, and clinical evidence for CAVT in pulmonary embolism and other vascular applications. Updates also include material agreements, shareholder voting matters, governance disclosures, and regulatory or clinical developments tied to Penumbra's thrombectomy and neurovascular products.

Rhea-AI Summary

Penumbra (NYSE: PEN) reported fourth-quarter 2025 revenue of $385.4M (+22.1%) and full-year 2025 revenue of $1,403.7M (+17.5%). Gross margin improved to 68.0% in Q4 and 67.1% for FY2025. Income from operations was $59.2M in Q4 and $189.2M for FY2025. Net income for Q4 was $47.3M and FY net income was $177.7M. The company will not provide 2026 guidance or host an earnings call due to the proposed acquisition by Boston Scientific (NYSE: BSX).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.27%
Tags
-
Rhea-AI Summary

Boston Scientific (NYSE: BSX) reported strong fourth-quarter 2025 results with Q4 net sales of $5.286 billion (+15.9% reported, +12.7% organic) and GAAP EPS of $0.45 (adjusted EPS $0.80). For full-year 2025, net sales were $20.074 billion (+19.9% reported) and adjusted EPS was $3.06. The company provided 2026 guidance of ~10.5–11.5% reported net sales growth and adjusted EPS of $3.43–3.49. Key developments include FDA/CE approvals for FARAPOINT PFA catheter, launches of SEISMIQ IVL and TheraSphere 360 clearance, enrollment and trial progress across AF, SCS and LAA closure studies, announced acquisitions of Penumbra and Valencia Technologies, and completion of the Nalu Medical acquisition.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.52%
Tags
-
Rhea-AI Summary

Penumbra (NYSE: PEN) provided unaudited, preliminary results for Q4 and full year 2025. Q4 revenue is estimated at $383.0M–$384.8M (+21.4% to +22.0% YoY; +23.2% to +23.8% ex-China). Full-year revenue is estimated at $1,401.3M–$1,403.1M (+17.3% to +17.5% YoY; +24.7% to +24.9% ex-China). Gross margin is ~67.9%–68.1% for Q4 and 67.1% for FY2025. Income from operations is $56.9M–$60.4M (Q4) and $186.9M–$190.4M (FY), implying operating margins of 14.8%–15.7% (Q4) and 13.3%–13.6% (FY).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.82%
Tags
Rhea-AI Summary

Boston Scientific (NYSE: BSX) agreed to acquire Penumbra (NYSE: PEN) in a cash-and-stock deal valuing Penumbra at $374 per share, implying an enterprise value of about $14.5 billion. Consideration is ~73% cash and ~27% stock, with a 3.8721 BSX share election per PEN share. Penumbra expects 2025 reported revenue of ~$1.4 billion (growth ~17.3%–17.5%) and Q4 growth ~21.4%–22.0%. Boston Scientific plans to finance roughly $11 billion of the cash portion with cash on hand and new debt. The deal is expected to close in 2026, subject to approvals, and to be mildly dilutive to adjusted EPS by $0.06–0.08 in year one, turning neutral/acc-retive thereafter.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.82%
Tags
-
Rhea-AI Summary

Penumbra (NYSE: PEN) announced its management team will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 6:45pm ET / 3:45pm PT.

A live webcast will be available on the company website under Investors > Events and Presentations and will remain accessible for at least two weeks after the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.20%
Tags
none
-
Rhea-AI Summary

Penumbra (NYSE: PEN) will present at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025 at 8:00 AM ET / 5:00 AM PT. A live webcast will be available via the company’s investor Events and Presentations page at www.penumbrainc.com and will remain on the site for at least two weeks after the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.19%
Tags
none
Rhea-AI Summary

Penumbra (NYSE: PEN) reported Q3 2025 revenue of $354.7 million, up 17.8% (16.9% constant currency) versus Q3 2024, with the U.S. representing 77.5% of sales. U.S. revenue rose 21.5%; U.S. thrombectomy sales were $192.0 million, up 18.5%. Gross profit was $240.4 million, or 67.8% gross margin. Income from operations was $48.8 million (13.8% operating margin) and net income was $45.9 million; adjusted EBITDA was $66.7 million (18.8% margin). SG&A increased to $168.9 million. The company raised full‑year 2025 revenue guidance to $1,375 million–$1,380 million (15%–16% growth) and reaffirmed U.S. thrombectomy growth guidance of 20%–21%. A conference call and webcast are scheduled for Nov 5, 2025 at 4:30 PM ET.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.32%
Tags
-
Rhea-AI Summary

Penumbra (NYSE:PEN) announced STORM-PE randomized controlled trial results (Nov 3, 2025) showing that CAVT plus anticoagulation produced significantly greater improvements versus anticoagulation alone in patients with acute intermediate-high risk pulmonary embolism.

Key numeric findings: refined modified Miller score reduction 42.1% vs 15.6% (2.7x; P<0.001), mean heart rate 80.0 vs 86.4 bpm (P=0.022), 90-day six-minute walk 472m vs 376m (P=0.019) and 94% vs 75% predicted walk distance (P=0.022). Safety through 90 days was comparable with no device-related mortality.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.52%
Tags
none
-
Rhea-AI Summary

Penumbra (NYSE: PEN) reported STORM-PE RCT results (Oct 27, 2025) showing computer assisted vacuum thrombectomy (CAVT) plus anticoagulation was superior to anticoagulation alone for intermediate-high risk pulmonary embolism.

Key results: 100 patients across 22 sites; greater mean reduction in RV/LV ratio at 48 hours (0.52 vs. 0.24; P<0.001); higher positive treatment effect rate (78.3% vs. 51.9%; P=0.011); comparable 7-day major adverse event rates (4.3% vs. 7.5%). Additional STORM-PE data to be presented at VEINS/VIVA (Nov 1-4, 2025).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.98%
Tags
none
Rhea-AI Summary

Penumbra (NYSE: PEN) will host an investor event at the 2025 TCT Conference on October 26, 2025 from 4:00–5:00 PM PT / 7:00–8:00 PM ET to discuss the STORM-PE clinical trial with management and the STORM-PE steering committee. A live webcast will be available on the company's Investors > Events and Presentations page and remain on the site for at least two weeks after the event.

The company also scheduled its Q3 2025 earnings release and conference call for after market close on November 5, 2025, with the call at 4:30 PM ET. The press release with third-quarter financial results will be issued after market close the same day. The conference call dial-in is (888) 596-4144 (conference id: 6572573) and a webcast will be available on the same investor events page for at least two weeks.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.94%
Tags
conferences earnings

FAQ

What is the current stock price of Penumbra (PEN)?

Penumbra (PEN) last closed at $320.01.

What is the market cap of Penumbra (PEN)?

The market cap of Penumbra (PEN) is approximately $12.6B.